No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
215 |
4. Check minimum number of eventsNone |
215 |
5. Include endpointsNone |
215 |
6. Filter based on genotype QC (FinnGen only) |
197 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
- Parent code in ICD-10
- E22
- Name in latin
- Hyperprolactinaemia
Similar endpoints
↥List of similar endpoints to
Hyperprolactinaemia, drug-induced
based on the number of shared cases.
Similar with more cases:
- Hyperprolactinaemia
- Hyperfunction of pituitary gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Exclusions for E4_PCOS_CONSORTIUM
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (not available in FinRegistry).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 197 | 170 | 27 |
| Unadjusted period prevalence (%) | 0.05 | 0.06 | 0.01 |
| Median age at first event (years) | 38.46 | 36.26 | 52.33 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 200
- Matched controls
- 2000
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G02CB01
ATC
bromocriptine; systemic
221.0
282.0
144
23
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
281.7
200
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
154.4
55.1
56
5
G02CB03
ATC
cabergoline; oral
169.9
50.5
51
*
XLA10, ,
NOMESCO Finland
13.3
50.1
54
54
G02CB04
ATC
quinagolide; oral
+∞
34.4
32
*
N04BC06
ATC
cabergoline; oral
101.9
31.9
34
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
49.5
22.0
26
6
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
+∞
16.9
16
*
G03DB01
ATC
dydrogesterone; oral
3.7
15.8
68
246
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
4.5
11.1
29
72
H02AB09
ATC
hydrocortisone; systemic
11.0
10.8
20
20
2531A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Other and unspecified anterior pituitary hyperfunction[HYPERPROLACTINAEMIA]
115.8
10.5
11
*
E23.00
ICD-10 Finland
Panhypopituitarism
115.8
10.5
11
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
42.4
10.1
12
*
N91.1
ICD-10 Finland
Secondary amenorrhoea
18.1
8.2
12
7
N05AX08
ATC
risperidone; systemic
3.7
7.8
26
77
XCK00
NOMESCO Finland
Perimetry
4.1
7.0
20
53
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
72.1
6.5
7
*
AA4BG
NOMESCO Finland
MRI examination of sella turcica with high intensity magnet
72.1
6.5
7
*
N05AA01
ATC
chlorpromazine; systemic, rectal
8.6
6.4
13
16
D44.8
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pluriglandular involvement
+∞
6.3
6
*
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
9.0
6.1
12
14
N05AB03
ATC
perphenazine; systemic, rectal
5.9
6.1
16
29
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
2.1
6.1
89
551
LC2AE
NOMESCO Finland
Ultrasound examination of uterus and parametria
2.6
6.1
38
164
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
62
369
1.99
4.52
2.9
2.4
2.45
2.44
mmol/l
0.32
53
337
8
14
5.90
3.37
4.1
17.4
841.89
1037.07
nmol/l
—
8
14
104
788
1.67
3.15
2.4
2.0
85.89
99.39
pmol/l
2.00
50
387
32
173
2.01
2.99
1.4
1.3
18.63
28.68
iu/l
1.64
27
149
115
920
1.59
2.62
3.8
3.1
87.02
91.43
ug/l
0.13
110
868
7
16
4.49
2.49
5.6
2.8
5.33
2.57
nmol/l
—
7
16
172
1538
1.85
2.37
29.0
18.4
330.42
331.14
g/l
0.47
172
1533
40
257
1.70
2.18
1.7
1.7
1152.54
1208.86
nmol/l
0.15
32
197
45
299
1.65
2.16
3.5
2.6
0.68
0.98
e6/l
0.52
26
146
18
90
2.10
2.08
1.9
1.7
—
—
—
0
0
59
425
1.55
2.03
3.1
2.2
2.60
2.81
mg/l
0.41
54
367
10
39
2.64
1.97
1.3
1.4
—
—
—
0
0
6
16
3.83
1.95
1.3
1.1
—
—
—
0
0
159
1416
1.60
1.93
4.8
4.4
13.63
10.76
mm/h
1.61
154
1331
31
192
1.73
1.92
2.3
1.9
—
—
—
0
0
32
202
1.70
1.86
2.1
1.8
—
—
—
0
0
46
320
1.57
1.83
4.4
3.4
36.29
258.76
ng/l
1.45
31
225
108
903
1.43
1.69
9.3
6.4
1.22
1.22
mmol/l
0.07
98
787
39
267
1.57
1.66
2.2
1.8
—
—
—
0
0
124
1071
1.42
1.57
15.4
10.2
3.95
3.81
e9/l
0.26
106
926
35
237
1.58
1.56
2.0
1.8
28.39
29.13
s
0.45
35
228
21
125
1.76
1.50
4.2
6.5
7.87
9.21
mmol/l
0.70
21
119
38
268
1.52
1.42
3.9
2.7
5.99
3.04
e6/l
0.50
20
114
112
966
1.36
1.34
5.0
3.6
0.09
0.00
estimate
0.79
22
198
66
524
1.39
1.33
2.1
1.6
18.33
21.68
nmol/l
1.34
59
446
61
482
1.38
1.26
3.7
2.9
0.26
0.48
e6/l
0.70
46
335
102
875
1.34
1.23
3.5
2.6
77.44
78.05
nmol/l
0.09
97
805
112
977
1.33
1.20
5.1
3.7
0.00
0.00
estimate
-0.00
25
203
181
1710
1.62
1.18
6.7
6.0
39.70
38.63
mmol/mol
0.95
175
1626
0
34
0.00
1.17
0.0
3.7
—
62.63
—
0
34
112
980
1.32
1.16
5.2
3.7
0.00
0.00
estimate
-0.00
23
192
5
21
2.42
1.09
1.6
1.3
—
—
—
0
0
188
1799
1.75
1.07
18.0
13.6
22.88
20.29
mg/l
0.47
148
1432
154
1420
1.37
1.06
8.9
8.0
77.56
77.89
u/l
0.04
149
1358
5
22
2.30
1.04
1.8
1.3
—
—
—
0
0
7
34
2.10
1.04
1.3
1.3
—
—
—
0
0
15
92
1.68
1.00
1.2
1.7
—
—
—
0
0
5
23
2.20
0.98
1.8
1.3
—
—
—
0
0
5
23
2.20
0.98
1.8
1.3
—
—
—
0
0
17
109
1.61
0.97
1.3
1.7
—
—
—
0
0
182
1736
1.54
0.95
7.8
5.9
1.79
1.85
mu/l
0.27
174
1621
9
52
1.76
0.93
6.0
4.6
27.94
146.14
mg/l
—
9
47
18
120
1.55
0.89
1.2
1.5
—
—
—
0
0
6
30
2.03
0.87
1.0
1.3
—
—
—
0
0
6
30
2.03
0.87
1.0
1.3
—
—
—
0
0
181
1730
1.49
0.86
4.8
4.3
1.37
1.26
mmol/l
1.04
174
1617
14
211
0.64
0.84
17.1
5.6
—
—
—
0
0
85
741
1.26
0.83
4.6
3.4
0.00
0.01
estimate
0.50
19
164
0
25
0.00
0.79
0.0
1.1
—
8.75
—
0
11
0
25
0.00
0.79
0.0
1.7
—
—
—
0
0
10
161
0.60
0.79
1.3
2.9
18.10
54.51
u/ml
—
10
154
5
24
2.11
0.75
2.0
1.4
3.85
2.94
u/ml
—
5
24
5
25
2.02
0.73
1.8
1.3
—
—
—
0
0
5
26
1.95
0.71
1.2
1.2
0.20
0.18
nmol/l
—
5
16
28
215
1.35
0.70
10.4
6.7
104.32
104.43
mmol/l
0.04
28
215
5
28
1.81
0.66
1.8
1.3
—
—
—
0
0
182
1757
1.40
0.64
5.7
5.0
5.84
5.81
mmol/l
0.09
177
1646
56
479
1.23
0.63
4.0
2.7
898.85
711.42
ng/l
0.20
49
393
10
63
1.62
0.63
1.0
1.3
—
61.39
—
0
11
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
8
52
1.56
0.60
6.5
4.6
26.76
27.82
mg/l
—
8
47
27
213
1.31
0.58
2.2
2.4
10.90
6.19
umol/l
0.50
22
186
10
65
1.57
0.56
1.3
1.3
—
—
—
0
0
53
456
1.22
0.56
2.3
2.5
324.33
310.91
umol/l
0.30
42
409
137
1289
1.20
0.54
3.0
3.2
42.25
40.71
u/l
0.09
130
1228
57
649
0.83
0.54
5.8
3.3
24.18
23.46
ng/l
0.03
32
408
21
164
1.31
0.49
1.7
1.4
—
—
—
0
0
65
579
1.18
0.48
4.1
3.9
7.22
6.23
mg/mmol
0.10
48
326
7
49
1.44
0.46
1.0
1.0
—
3.20
—
0
8
60
534
1.18
0.45
3.5
3.1
0.06
0.01
estimate
0.35
17
160
93
858
1.16
0.44
2.0
2.0
1.54
1.34
mmol/l
1.10
82
731
8
58
1.39
0.42
1.3
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
2.0
—
15.88
—
0
8
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
8
60
1.35
0.41
1.0
1.3
—
0.88
—
0
5
188
1842
1.34
0.39
6.8
5.9
2.87
2.86
mmol/l
0.11
183
1733
180
1755
1.26
0.38
17.2
13.6
82.62
83.37
ml/min/173m2
0.24
173
1630
20
162
1.26
0.37
6.3
4.5
18.32
21.58
%
—
6
74
12
90
1.35
0.36
1.2
1.5
—
—
—
0
0
6
41
1.48
0.36
1.3
1.6
—
—
—
0
0
22
182
1.23
0.35
2.1
1.7
—
—
—
0
0
125
1190
1.13
0.34
3.2
3.2
—
—
—
0
0
50
449
1.15
0.33
1.5
1.5
—
—
—
0
0
48
432
1.15
0.31
2.4
1.6
1.05
1.01
mg/l
0.06
40
353
55
501
1.13
0.30
1.3
1.3
0.74
2.12
u/ml
0.97
12
158
7
55
1.28
0.30
1.1
1.2
—
—
—
0
0
20
167
1.22
0.30
2.1
1.7
—
—
—
0
0
7
56
1.26
0.29
3.3
1.6
0.46
1.46
ug/l
—
7
51
7
57
1.24
0.29
2.3
1.5
—
—
—
0
0
8
66
1.22
0.27
1.4
1.8
—
—
—
0
0
185
1820
1.22
0.25
5.7
5.1
1.47
1.56
mmol/l
2.43
179
1711
6
81
0.73
0.24
1.0
1.2
0.87
0.90
g/l
—
6
81
5
40
1.26
0.22
2.8
2.3
—
—
—
0
0
5
41
1.23
0.22
2.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
24.44
—
0
10
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
7.75
—
0
12
0
12
0.00
0.21
0.0
2.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
47
434
1.11
0.21
5.8
3.6
1.02
1.02
kg/l
0.14
34
286
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
6
50
1.21
0.20
1.8
2.6
—
—
—
0
0
6
51
1.18
0.19
1.2
1.2
—
—
—
0
0
13
109
1.21
0.19
1.4
1.4
—
—
—
0
0
6
53
1.14
0.19
2.0
1.5
18.75
33.10
u/l
—
6
46
12
100
1.21
0.18
2.1
3.6
24.94
24.54
mmol/l
0.19
12
100
7
59
1.19
0.18
1.3
1.1
—
—
—
0
0
40
430
0.91
0.16
2.5
2.2
—
—
—
0
0
15
172
0.86
0.16
1.3
1.9
3.56
3.49
mmol/l
—
7
133
32
294
1.11
0.16
4.7
2.6
0.80
0.82
mmol/l
0.49
32
280
6
79
0.75
0.16
1.0
1.2
1.45
1.63
g/l
—
6
79
9
81
1.12
0.15
1.1
1.3
—
—
—
0
0
16
141
1.15
0.14
1.3
1.3
—
40.12
—
0
6
16
180
0.88
0.14
1.1
1.2
122.66
187.74
u/ml
—
5
79
9
105
0.85
0.13
1.6
1.5
—
—
—
0
0
21
228
0.91
0.10
1.5
2.1
3.47
3.35
ratio
0.17
14
189
5
48
1.04
0.09
2.2
1.5
—
—
—
0
0
6
54
1.11
0.09
2.5
2.0
184.00
180.35
%
—
6
54
6
57
1.05
0.08
2.5
1.5
—
—
—
0
0
102
999
1.04
0.08
7.1
6.3
11.73
10.47
umol/l
0.38
96
953
8
78
1.03
0.07
1.5
1.7
—
—
—
0
0
40
415
0.95
0.06
1.5
1.3
1.25
9.30
u/ml
3.12
20
168
16
171
0.93
0.05
1.7
2.5
82.75
71.89
ml/min/173m2
—
8
66
54
527
1.03
0.04
5.0
3.7
0.00
0.00
estimate
-0.00
23
189
39
379
1.04
0.03
1.5
1.5
—
—
—
0
0
14
149
0.94
0.03
2.7
3.2
—
—
—
0
0
82
831
0.98
0.03
2.7
2.6
—
—
estimate
—
0
0
10
106
0.94
0.01
1.0
1.1
—
—
—
0
0
46
457
1.01
0.00
1.5
1.3
11.48
27.53
iu/ml
2.56
16
150
11
108
1.02
0.00
14.3
7.3
26.45
25.44
mmol/l
0.40
11
108
18
178
1.01
0.00
2.9
2.5
43.85
28.62
u/l
0.38
13
141
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
4.1
—
4.72
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
4.1
—
11.13
—
0
7
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
44.85
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
8.68
—
0
9
0
9
0.00
-0.00
0.0
1.4
—
199.44
—
0
9
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
49
1.02
-0.00
2.2
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
8.76
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (not available in FinRegistry).
Relationships between endpoints
↥Index endpoint: E4_HYPERPRO_ADVERSE – Hyperprolactinaemia, drug-induced
GWS hits: -
This endpoint is excluded (not available in FinRegistry).